Skip to main content
MRMD
OTC Life Sciences

Q1 Results Show Improved Profitability; DOJ Cannabis Rescheduling Offers Major Tax Relief

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.082
Mkt Cap
$32.512M
52W Low
$0.064
52W High
$0.23
52W Position info
27% above low
Off High info
65% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MRMD sits 27% above its 52-week low of $0.064.

Summary

MariMed reported improved Q1 financials with a narrower net loss and higher Adjusted EBITDA, while the recent DOJ decision to reschedule cannabis to Schedule III is expected to significantly boost future profitability by removing a major tax burden.


Key Events · Legal and Risk Events · MRMD

  • Improved Q1 Financial Performance

    For Q1 2026, MariMed reported revenue of $39.481 million (up 4.2% from Q1 2025), a net loss of $(3.767) million (improved from $(5.479) million in Q1 2025), and Adjusted EBITDA of $3.582 million (up 43% from Q1 2025).

  • DOJ Reschedules Cannabis to Schedule III

    The U.S. Department of Justice's final order on April 23, 2026, placed FDA-approved and state medical cannabis in Schedule III of the Controlled Substances Act. This change eliminates IRC Section 280E tax limitations for these categories, allowing full deduction of business expenses, which is a significant positive for future profitability.

  • Debt Restructuring Completed

    On February 24, 2026, the company restructured its Series B Convertible Preferred Stock obligation, extinguishing a $14.2 million liability. This was replaced by $8.0 million in new promissory notes and 26.9 million shares of new Series B Preferred Stock with a $6.725 million liquidation preference, resulting in a $0.7 million gain on extinguishment of debt.

  • Ongoing IRS Tax Lien Disputes

    The company continues to dispute IRS tax liens totaling $7 million ($1 million against FSC and $6 million against MariMed), which are fully accrued in the financials but remain an unresolved risk.


Analysis · MRMD · Life Sciences

MariMed Inc.'s Q1 2026 results indicate improved operational performance with a narrower net loss and a significant increase in Adjusted EBITDA. The most impactful development, however, is the U.S. Department of Justice's decision on April 23, 2026, to reschedule certain cannabis products to Schedule III. This change removes the burdensome IRC Section 280E tax limitations for FDA-approved and state medical cannabis, which is a transformative positive for the company's future profitability, although its financial impact is not yet reflected in these Q1 results. The company also detailed a debt restructuring that resulted in a $0.7 million gain on extinguishment, replacing a prior preferred stock obligation with new notes and new preferred stock. Ongoing IRS tax liens totaling $7 million remain a risk, though they are currently being disputed. New employment agreements for the CFO and CCO provide executive stability.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $0.06 to $0.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRMD - Latest Insights

MRMD
Oct 29, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.053
Real-time Price: $0.0736 info
Change: +$0.0206 (+39%) info
Market Cap: $30.434M info
MRMD
Sep 22, 2026, 4:42 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.0732
Real-time Price: $0.0736 info
Change: +$0.0004 (+0.55%) info
Market Cap: $30.434M info
MRMD
Sep 11, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.0788
Real-time Price: $0.0736 info
Change: -$0.0052 (-7%) info
Market Cap: $30.434M info
MRMD
Aug 13, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.065
Real-time Price: $0.0736 info
Change: +$0.0086 (+13%) info
Market Cap: $30.434M info
MRMD
Aug 12, 2026, 5:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.06405
Real-time Price: $0.0736 info
Change: +$0.00955 (+15%) info
Market Cap: $30.434M info